Pay in 4 interest-free payments of $5.08 Learn more
Ships within 48 hours · Estimated delivery Aug 18 - Aug 23
The marketing is compelling
Not every patient who used a GLP-1 drug will qualify for legal action
Grech O, Mitchell JL, Lyons HS, Yiangou A, Thaller M, Tsermoulas G et al (2024) Effect of glucagon like peptide-1 receptor agonist exenatide, used as an intracranial pressure lowering agent, on cognition in idiopathic intracranial hypertension
Patient characteristics such as poorer blood glucose control, higher body mass, and shorter duration of diabetes predict better response to medications that target the GLP-1 pathway
Some individuals report feeling more energetic due to improved glycaemic control and weight loss, whilst others may notice increased tiredness, particularly in the early treatment phase
